Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + Ribavirin

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Thrombocytopenia

Conditions

Thrombocytopenia

Trial Timeline

Nov 1, 2011 → May 1, 2014

NCT ID

NCT01355289

About Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + Ribavirin

Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + Ribavirin is a phase 2 stage product being developed by Eisai for Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01355289. Target conditions include Thrombocytopenia.

What happened to similar drugs?

2 of 20 similar drugs in Thrombocytopenia were approved

Approved (2) Terminated (2) Active (16)

✅Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved

✅romiplostimAmgenApproved

🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3

🔄Avatrombopag + Placebo + Standard of careEisaiPhase 3

🔄Romiplostim + PlaceboKyowa KirinPhase 3

🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01355289	Phase 2	Completed	Nov 1, 2011	May 1, 2014	Thrombocytopenia

Competing Products

20 competing products in Thrombocytopenia

See all competitors

Product	Company	Stage	Hype Score
Pirtobrutinib + Placebo	Eli Lilly	Phase 1/2	39
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	17
Placebo + Lusutrombopag	Shionogi	Phase 2	27
Lusutrombopag	Shionogi	Phase 2	27
Avatrombopag + Avatrombopag + Placebo	Eisai	Phase 2	35
avatrombopag	Eisai	Phase 1	29
E5501 + Drug: E5501	Eisai	Phase 1	29
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)	Eisai	Phase 3	40
avatrombopag + Placebo	Eisai	Phase 2	35
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)	Eisai	Phase 3	40
Avatrombopag + Placebo + Standard of care	Eisai	Phase 3	40
Romiplostim	Kyowa Kirin	Phase 1/2	32
Romiplostim + Placebo	Kyowa Kirin	Phase 3	40
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	35
Romiplostim and danazol	Kyowa Kirin	Phase 2	31
ONO-7746	Ono Pharmaceutical	Phase 1	21
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	29
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo	Jiangsu Hengrui Medicine	Phase 3	47
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 2	42
TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)	Jiangsu Hengrui Medicine	Phase 2	31